AbbVie's (ABBV) Buy Rating Reiterated at Guggenheim

Key Points

• Guggenheim reiterated a Buy on AbbVie with a $249 price target, implying roughly a 19.7% upside from the current share price.
• AbbVie posted a Q1 beat (EPS $2.65 vs. $2.59; revenue $15.0B vs. $14.72B) and raised its 2026 EPS outlook, with momentum driven by Skyrizi, Rinvoq and Botox.
• The consensus from analysts is a Moderate Buy with an average target of $252.90, compared with a current stock price near $208 and recent insider selling reported.

AbbVie (NYSE:ABBV - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Guggenheim in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $249.00 price target on the stock. Guggenheim's price objective points to a potential upside of 19.65% from the company's current price.

Other equities research analysts have also issued research reports about the stock. The Goldman Sachs Group reiterated a "neutral" rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Weiss Ratings reiterated a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Canaccord Genuity Group increased their price objective on shares of AbbVie from $262.00 to $265.00 and gave the stock a "buy" rating in a research note on Thursday. Royal Bank Of Canada began coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target on the stock. Finally, Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $252.90.

AbbVie Stock Performance

Shares of ABBV stock traded down $3.22 during trading hours on Friday, hitting $208.10. 2,121,099 shares of the company were exchanged, compared to its average volume of 7,178,282. AbbVie has a one year low of $176.57 and a one year high of $244.81. The business's 50-day simple moving average is $214.55 and its two-hundred day simple moving average is $221.60. The stock has a market capitalization of $367.96 billion, a price-to-earnings ratio of 102.50, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. AbbVie's quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 earnings per share. As a group, analysts anticipate that AbbVie will post 14.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Chelsea Counsel Co. acquired a new stake in AbbVie in the 3rd quarter worth $26,000. Litman Gregory Wealth Management LLC acquired a new position in AbbVie in the fourth quarter valued at about $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.3% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares in the last quarter. Westend Capital Management LLC acquired a new position in AbbVie in the fourth quarter valued at about $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new position in AbbVie in the fourth quarter valued at about $31,000. Institutional investors own 70.23% of the company's stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and guidance lift: AbbVie reported better-than-expected Q1 results and raised its 2026 EPS outlook, driven by Skyrizi, Rinvoq and Botox strength — a primary reason for recent upside momentum. AbbVie stock gains, 2026 guidance hike
• Positive Sentiment: Bank of America upgrade: BofA upgraded ABBV to Buy and lifted its price target, signaling growing confidence that Skyrizi/Rinvoq can offset Humira declines and supporting upside sentiment. AbbVie NYSE: ABBV Rating Increased to Buy at Bank of America
• Positive Sentiment: Morgan Stanley raised its price target to $278, reinforcing bullish analyst views and adding to momentum for the stock. AbbVie had its price target raised by Morgan Stanley
• Positive Sentiment: Canaccord also lifted its target and maintains a buy stance, adding to the cluster of upward analyst revisions. Canaccord raises price target on AbbVie
• Neutral Sentiment: Competitive positioning: AbbVie laid out how Skyrizi will compete versus J&J’s new Icotyde in plaque psoriasis — shows management focus on defending market share but also highlights an evolving competitive landscape. AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
• Neutral Sentiment: Corporate outreach/PR: AbbVie awarded a biotech innovators prize (RIME Therapeutics) — positive for long-term innovation positioning but unlikely to move near-term revenue. AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
• Negative Sentiment: Pipeline trimming: While Q1 beat was strong, AbbVie announced it is discontinuing a cancer candidate — a small headwind to R&D optionality that can temper enthusiasm about growth catalysts. AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
• Negative Sentiment: Analyst estimate tweaks: Erste Group trimmed FY2026/FY2027 EPS estimates slightly, signaling some caution beneath the upbeat headline numbers — contributes to mixed investor sentiment. MarketBeat AbbVie analyst notes (Erste Group)

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.